Divi's Laboratories — Q4 FY25
Divis Laboratories reported a strong Q4 FY25 with PAT of INR 662 crore, up 23% YoY, driven by robust custom synthesis momentum and stable generic volumes despite pricing headwinds.
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY25
Kakinada Phase I full commissioning in 6 months
The remaining part of Phase I at Kakinada is expected to be operational in about six months.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1